… patients with acute, prolonged, convulsive seizures. This article reviews the pharmacologic
properties of oromucosal midazolam and its … in pediatric patients aged 3 months to <18 years. …

… , is approved in the EU for the treatment of paediatric patients (aged 3 months to <18 years)
… trials in children with prolonged, acute, convulsive seizures, oromucosal midazolam was at …

… In this study, we present the economic model populated with the Welsh data assessing the
cost effectiveness of Buccolam ® for those paediatric patients with a diagnosis of epilepsy …

… midazolam and rectal diazepam in pediatric patients. The results from various clinical studies
showed that buccal midazolam … midazolam is also a more acceptable choice to the patients…

… The results of this study show that a 10-mg dose of oromucosal midazolam maleate is used
most often as rescue medication for adults with epilepsy and is effective when administered …

… midazolam hydrochloride oromucosal solution (MHOS) that can be simply and rapidly
administered to patients … -administered drugs, midazolam hydrochloride oromucosal solution (…

… Sedation is frequently desired to facilitate dental procedures in uncooperative paediatric
patients. Oromucosal Midazolam sedation is a popular choice among paediatric dentists world …

… midazolam has emerged as an effective rescue therapy for prolonged seizures among
paediatric patients, and … oromucosal product in the United Kingdom, as well as the first to receive …

… midazolam is usually given first to increase patient cooperation. Given that buccal midazolam
… palatable buccal midazolam by intravenous midazolam hydrochloride formulation …

… This study assessed the efficacy and safety of buccally administered midazolam hydrochloride
oromucosal solution administered by trained caregivers to pediatric patients with SE in …